Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

Virtual Education Program - COLT Meeting 2018 (Session 1)

-- Virtual Education Program: 2018 Edition

 

Presentations from the COLT Meeting 2018

We are pleased to make available a series of presentations from the COLT Meeting 2018, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, practicalities on CML management, TFR in CML, CML related topics and the CML frontier.

Timothy Hughes.pngDavid Yeung 3Devendra Hiwase

 

 

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • CML - current clinical issues
    and future directions 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 


Timothy Hughes

  

 

CML - Current clinical issues and future directions
Prof. Tim Hughes, SAHMRI / University of Adelaide

  • Key issues and possible solutions
  • Essential tests at diagnosis
  • Expected outcome for patients treated with frontline imatinib
  • Risk-adapted/goal specific treatment schema
  • Consensus of opinion on TKI choices
  • Results from the TIDEL II trial in Australia/NZ
  • Results from the TARGET survey
  • ABL001 - specific inhibitor of BCR-ABL1
 

 
David Yeung 3  


When frontline therapy fails
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

  • LASOR - failure to achieve 2019 ELN goals
  • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
  • ENESTCmr - failure to achieve deep molecular response
  • Ponatinib - drug of last resort
  • Asciminib (ABL001) - rising star?

Devendra Hiwase		  

 

CML - Beyond chronic phase
Dr Devendra Hiwase - SA Pathology / Royal Adelaide Hospital

  • Diagnostic and management issues in CML-AP
    • Definitions of AP
    • Survival benefit with Imatinib in CML-AP
    • Study results on NIL, DAS and PON in patients with CML-AP
    • Imatinib vs. allogeneic SCT in CML-AP patients
    • Treatment strategy recommendations for CML-AP
    • Patient case
  • Diagnostic criteria and management of blast crisis
    • Transformation to blast crisis
    • Survival of CML-BC patients: German CML studies I to IIIA
    • Outcome of blast crisis in the era of TKI therapy
    • Management issues in CML-BC
    • Further treatment options in CML-BC
    • Patient case